Zevra Therapeutics (ZVRA) Cash & Equivalents (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Cash & Equivalents data on file, last reported at $95.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 156.01% year-over-year to $95.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.6 million (up 156.01% YoY) and the FY2025 annual result came in at $62.4 million, up 84.72% from the prior year.
• Cash & Equivalents improved to $95.6 million in Q1 2026, from $62.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $95.6 million in Q1 2026 to a low of $33.8 million in Q4 2024.
• A 5-year average of $53.7 million and a median of $47.7 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 46.72% — and 2026, when it jumped 156.01%.
• Tracing ZVRA's Cash & Equivalents over 5 years: stood at $65.5 million in 2022, then sank by 34.24% to $43.0 million in 2023, then retreated by 21.52% to $33.8 million in 2024, then soared by 84.72% to $62.4 million in 2025, then surged by 53.18% to $95.6 million in 2026.
• The last three Cash & Equivalents figures came in at $95.6 million (Q1 2026), $62.4 million (Q4 2025), and $54.4 million (Q3 2025), per Business Quant data.